Guerbet : FY 2023 earnings: ahead of plan and 2024 guidance looks different
>EBITDA beats expectations - 2023 EBITDA came in at € 98.8m, up 4% (consensus: € 88m est.). Net profit worked out at € 22m vs -€ 41m at end-2022 (consensus: € 9.8m est.).Free cash flow stood at -€ 65.4m in 2023; in the second half alone, it was positive at € 6.6m. Net debt worked out at € 335m vs € 270m at year-end 2022.Guerbet reiterated its guidance: 8% growth LfL with a target adjusted EBITDA margin ahead of the level seen in 2021 (14.4%).A stable di...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.